Shudi Luo

Shudi Luo

Auto-generated profile, based on publicly available information

Shudi Luo

Zhejiang University School of Medicine 1 Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, and Institute of Translational Medicine Hangzhou

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Protein & Cell
Verified
Journal Article
Open access
PDF file
DGDong Guo
Dong Guo
HHHaiyan He
Haiyan He
YMYing Meng
Ying Meng
SLShudi Luo
Shudi Luo
ZLZhimin Lu
Zhimin Lu
The tricarboxylic acid (TCA) cycle identified in 1937 by Hans Adolf Krebs and William Arthur Johnson (also known as the Krebs cycle or citric acid cycle) is a central route for oxidative metabolism to generate cellular energy and intermediates for the biosynthesis of amino acids, lipids, and nucleic acids ( Krebs and Johnson 1937). The TCA cycle connects carbohydrate, fat, and protein metabolism and converts these nutrient catabolism-derived acetyl-CoA into carbon dioxide and water, with the production of reduced NAD+ (NADH), reduced flavin adenine dinucleotide (FADH2), and guanosine triphosphate (GTP). The generated NADH and FADH2 are, in turn, used by the oxidative phosphorylation pathway to generate energy-rich adenosine triphosphate (ATP) ( Chakrabarty and Chandel 2021).

28 November 2023 in Hepatology
Verified
Journal Article
Closed access
GZGaoxiang Zhao
Gaoxiang Zhao
QMQingxia Ma
Qingxia Ma
HYHuang Yang
Huang Yang
HJHongfei Jiang
Hongfei Jiang
QXQianqian Xu
Qianqian Xu
ZLZhimin Lu
Zhimin Lu
Background and Aims: Base editing has shown great potential for treating human diseases with mutated genes. However, its potential for treating HCC has not yet been explored. Approach and Results: We employed adenine base editors (ABEs) to correct a telomerase reverse transcriptase (TERT) promoter mutation, which frequently occurs in various human cancers, including HCC. The mutated TERT promoter −124 C>T is corrected to −124 C by a single guide (sg) RNA-guided and deactivated Campylobacter jejuni Cas9 (CjCas9)-fused adenine base editor (CjABE). This edit impairs the binding of the E-twenty six/ternary complex factor transcription factor family, including E-twenty six-1 and GABPA, to the TERT promoter, leading to suppressed TERT promoter and telomerase activity, decreased TERT expression and cell proliferation, and increased cell senescence. Importantly, injection of adeno-associated viruses expressing sgRNA-guided CjABE or employment of lipid nanoparticle-mediated delivery of CjABE mRNA and sgRNA inhibits the growth of liver tumors harboring TERT promoter mutations. Conclusions: These findings demonstrate that a sgRNA-guided CjABE efficiently converts the mutated TERT promoter −124 C>T to −124 C in HCC cells and underscore the potential to treat HCC by the base editing-mediated correction of TERT promoter mutations.

6 March 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
WQWenxing Qin
Wenxing Qin
YDYuran Duan
Yuran Duan
ZHZhiqiang Hu
Zhiqiang Hu
YHYueru Hou
Yueru Hou
TWTing Wen
Ting Wen
DXDaqian Xu
Daqian Xu
Hypoxia induces immunosuppressive phenotypes in tumor cells even in the presence of cytosolic DNA accumulation. The mechanisms by which tumor cells suppress hypoxia-induced cGAS-STING activation for immune evasion remain largely unclear. Here, we demonstrate that hypoxic stimulation induces JNK1/2-mediated S151 phosphorylation of phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis. This phosphorylation triggers the interaction between PCK1 and cGAS. The PCK1 associated with cGAS competitively consumes GTP, a substrate shared by both PCK1 and cGAS. Consequently, PCK1 inhibits GTP-dependent cGAS activation and subsequent STING-promoted immune cell infiltration and activation in the tumor microenvironment, leading to promoted tumor growth in mice. The blockade of PCK1 function, in combination with anti–PD-1 antibody treatment, exhibits an additive therapeutic effect on tumor growth. Additionally, PCK1 S151 phosphorylation is inversely correlated with cGAS-STING activation in human breast cancer specimens and patient survival. These findings reveal a novel regulation of cGAS-STING pathway and uncover the metabolic control of immune response in tumor cells.